Utilidad de un test rápido de interleuquina-6 sérico combinado con proteína C reactiva para predecir la sepsis en recién nacidos con sospecha de infección

Mosquera, José Beceiro; Monzo, C.; Salguero, O. Oria de Rueda; Soria, C; Nory, C. Herbozo

doi:10.1016/j.anpedi.2009.07.027

Cited by 10 publications

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…6 En particular la IL-6 y 10 se incrementan rápidamente durante la sepsis y se han asociado a mayor incidencia de choque séptico y muerte, 7 de ahí su interés para considerarlas como marcadores tanto diagnósticos como pronósticos. [8][9][10] La interleucina 6 (IL-6) puede ser detectada en el suero entre una a dos horas de la invasión de una bacteria. En particular las bacterias Gram negativas activan la respuesta de los macrófagos a través de su endotoxina en la liberación de citocinas como la IL-6.…”

Section: Introductionunclassified

Utilidad de la interleucina 6 para diferenciar sepsis de etiología bacteriana y viral en pacientes pediátricos

Quiñonez Ávila,

Garay Carmona,

Casillas Casillas

et al. 2023

Medicina Crítica

View full text Add to dashboard Cite

show abstract

Section: Introductionunclassified

Utilidad de la interleucina 6 para diferenciar sepsis de etiología bacteriana y viral en pacientes pediátricos

Quiñonez Ávila,

Garay Carmona,

Casillas Casillas

et al. 2023

Medicina Crítica

View full text Add to dashboard Cite

show abstract

“…Importantly, there is no physiological elevation of IL-6 in newborns. Numerous studies support its use as an early marker of sepsis, particularly associated with other markers [25][26][27][28][29][30][31][32][33][34][35][36] .…”

Section: Introductionmentioning

confidence: 99%

Antibiotherapy at birth in very low birth weight infants before and after the use of interleukin 6 as an infectious biomarker in a tertiary level unit

Lareu-Vidal¹,

Solı́s²,

Caunedo-Jiménez³

et al. 2021

BMHIM

View full text Add to dashboard Cite

Background: Neonatal sepsis is a condition with high mortality and morbidity that contributes to high rates of antibiotic therapy at birth. In addition, very low birth weight newborns (VLBWN) are particularly vulnerable. Interleukin 6 (IL-6) seems to be an early and effective marker that could help a better selection of patients to be treated. This study aimed to evaluate the use of antibiotics in the first 72 hours of life in VLBW infants before and after using IL-6 as an infection marker. Also, we wanted to analyze the differences in morbidity and mortality during admission and other factors associated with the decision to start antibiotic treatment. Methods: We conducted a cohort retrospective study. We included VLBWN born in our hospital or admitted before 72 hours of life in two two-year periods (2007-2008 and 2011-2012). Results: Antibiotics use during the first 72 hours of life was analyzed as the primary variable, which was reduced by 20% on the second period (p = 0.002). Regarding the analysis of secondary variables, we found no significant differences in mortality during hospital admission and the incidence of nosocomial sepsis, enterocolitis, or invasive fungal infection. The multivariate analysis indicated extreme prematurity and the study group as the most strongly related factors to the start of antibiotic therapy. Conclusions: IL-6 was a useful marker of infection to reduce the use of antibiotic therapy in VLBW infants without increasing mortality.

show abstract

C-reactive protein for diagnosing late-onset infection in newborn infants

Brown

Meader

Cleminson

et al. 2019

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Background Late-onset infection is the most common serious complication associated with hospital care for newborn infants. Because confirming the diagnosis by microbiological culture typically takes 24 to 48 hours, the serum level of the inflammatory marker C-reactive protein (CRP) measured as part of the initial investigation is used as an adjunctive rapid test to guide management in infants with suspected late-onset infection. Objectives To determine the diagnostic accuracy of serum CRP measurement in detecting late-onset infection in newborn infants. Search methods We searched electronic databases (MEDLINE, Embase, and Science Citation Index to September 2017), conference proceedings, previous reviews, and the reference lists of retrieved articles. Selection criteria We included cohort and cross-sectional studies evaluating the diagnostic accuracy of serum CRP levels for the detection of late-onset infection (occurring more than 72 hours after birth) in newborn infants. Data collection and analysis Two review authors independently assessed eligibility for inclusion, evaluated the methodological quality of included studies, and extracted data to estimate diagnostic accuracy using hierarchical summary receiver operating characteristic (SROC) models. We assessed heterogeneity by examining variability of study estimates and overlap of the 95% confidence interval (CI) in forest plots of sensitivity and specificity. Main results The search identified 20 studies (1615 infants). Most were small, single-centre, prospective cohort studies conducted in neonatal units in high-or middle-income countries since the late 1990s. Risk of bias in the included studies was generally low with independent assessment of index and reference tests. Most studies used a prespecified serum CRP threshold level as the definition of a 'positive' index test (typical cutoff level between 5 mg/L and 10 mg/L) and the culture of a pathogenic microorganism from blood as the reference standard.

show abstract

Utilidad de un test rápido de interleuquina-6 sérico combinado con proteína C reactiva para predecir la sepsis en recién nacidos con sospecha de infección

Cited by 10 publications

References 17 publications

Utilidad de la interleucina 6 para diferenciar sepsis de etiología bacteriana y viral en pacientes pediátricos

Utilidad de la interleucina 6 para diferenciar sepsis de etiología bacteriana y viral en pacientes pediátricos

Antibiotherapy at birth in very low birth weight infants before and after the use of interleukin 6 as an infectious biomarker in a tertiary level unit

C-reactive protein for diagnosing late-onset infection in newborn infants

Contact Info

Product

Resources

About